QVT Financial
VC Fund
New York, United States
QVT Financial is a VC fund in New York focused on Biotechnology and Health Care. QVT Financial LP is a privately owned hedge fund sponsor. The firm provides its services to pooled investment vehicles. It invests in public equity and debt across the globe. The firm also invests in alternative investment markets across the globe. It invests in structured finance, private placements, high yield, and distressed debt to create itsportfolios. The firm employs convertible arbitrage, investment grade, and capital structure arbitrage techniques along with closed-end fund arbitrage and various relative value-driven equity strategies such as risk arbitrage, fundamental relative value, statistical trades, and other special situation techniques to its investments. QVT Financial is based in New York, New York with an additional office in London, United Kingdom.
- Total investments:
- 31
- Last investment:
- Lead investor:
- 13%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries QVT Financial invests in
Stages QVT Financial invests in
Countries QVT Financial invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Dan Collins
|
|||
Daniel A. Gold
|
|||
|
Lars E. Bader
|
|||
|
Nicholas Brumm
|
|||
Tracy Fu
|
Investment Focus
Industry
- Biotechnology 19 (61%)
- Health Care 12 (39%)
- Biopharma 8 (26%)
- Therapeutics 8 (26%)
- Pharmaceutical 8 (26%)
Stage
- Series A 6 (19%)
- Post-IPO Equity 6 (19%)
- Series C 5 (16%)
- Series B 4 (13%)
- Funding Round 3 (10%)
Country
- United States 19 (61%)
- Israel 2 (6%)
- United Kingdom 2 (6%)
- Canada 1 (3%)
- France 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Dan Collins
Partner & Chief Operating Officer
|
Partner & Chief Operating Officer | Total investments: 0 | Find email | |
|
Daniel A. Gold
Managing Partner and CEO
|
Managing Partner and CEO | Total investments: 0 | Find email | |
|
Lars E. Bader
Portfolio Manager
|
Portfolio Manager | Total investments: 0 | Find email | |
|
Nicholas Brumm
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
|
Tracy Fu
Managing Partner
|
Managing Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Whitehawk Therapeutics
|
Aadi Bioscience was founded by Dr. Neil Desai, is a clinical-stage biopharmaceutical company developing the potentially best-in-class mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases. | $87.5M / Post-IPO Equity / May 13, 2026 | |
Syremis Therapeutics
|
Syremis Therapeutics is developing novel medicines to make a profound impact on the treatment of mental health disorders. | $165M / Series A / Dec 18, 2025 | |
QuEra Computing
|
QuEra Computing is a company focused on developing quantum computing technology. They specialize in building large-scale quantum computers using neutral atoms. QuEra uses innovative techniques to manipulate and control qubits for quantum computation, aiming to solve complex problems in fields like chemistry, materials science, and machine learning.Their quantum computers operate on a platform that leverages arrays of neutral atoms that are highly scalable, providing a path toward achieving quantum advantage for practical applications. | Convertible Note / Feb 11, 2025 | |
|
QuEra Computing
|
QuEra Computing is a company focused on developing quantum computing technology. They specialize in building large-scale quantum computers using neutral atoms. QuEra uses innovative techniques to manipulate and control qubits for quantum computation, aiming to solve complex problems in fields like chemistry, materials science, and machine learning.Their quantum computers operate on a platform that leverages arrays of neutral atoms that are highly scalable, providing a path toward achieving quantum advantage for practical applications. | $230M / Series B / Feb 11, 2025 | |
Lightsynq
|
Lightsynq develops universal optical quantum interconnects that bridge the gap to large-scale quantum computers. | $18M / Series A / Nov 19, 2024 | |
Active Surfaces
|
Active Surfaces is commercializing MIT-developed ultra-thin-film solar technology. | $5.6M / Pre-Seed / May 13, 2024 | |
Kriya Therapeutics
|
Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases. We target conditions where the underlying biology is well-understood, rationally designing one-time gene therapies to durably express therapeutic proteins within the appropriate humantissues. Our team has deep expertise in the field and includes former senior leadership from pioneering gene therapy companies and academic institutions. We use algorithmic tools, scalable infrastructure, and proprietary technology to optimize the efficacy and durability of our gene therapies – with a goal of transforming the treatment paradigm for some of the most serious and widespread diseases. | $270M / Series C / May 16, 2022 | |
Tourmaline Bio
|
Tourmaline Bio is a clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients and prevent immune diseases. | Seed / May 01, 2022 | |
|
Kriya Therapeutics
|
Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases. We target conditions where the underlying biology is well-understood, rationally designing one-time gene therapies to durably express therapeutic proteins within the appropriate humantissues. Our team has deep expertise in the field and includes former senior leadership from pioneering gene therapy companies and academic institutions. We use algorithmic tools, scalable infrastructure, and proprietary technology to optimize the efficacy and durability of our gene therapies – with a goal of transforming the treatment paradigm for some of the most serious and widespread diseases. | $100M / Series B / Jul 14, 2021 | |
|
Kriya Therapeutics
|
Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases. We target conditions where the underlying biology is well-understood, rationally designing one-time gene therapies to durably express therapeutic proteins within the appropriate humantissues. Our team has deep expertise in the field and includes former senior leadership from pioneering gene therapy companies and academic institutions. We use algorithmic tools, scalable infrastructure, and proprietary technology to optimize the efficacy and durability of our gene therapies – with a goal of transforming the treatment paradigm for some of the most serious and widespread diseases. | $80.5M / Series A / May 12, 2020 | |
| See all 31 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does QVT Financial invest in?
QVT Financial invests primarily in Biotechnology, Health Care and Biopharma startups, most often at Series A and Post-IPO Equity stage. Most of the 31 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact QVT Financial?
Public channels for QVT Financial include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at QVT Financial?
The team at QVT Financial includes Dan Collins (Partner & Chief Operating Officer), Daniel A. Gold (Managing Partner and CEO) and Lars E. Bader (Portfolio Manager). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
